Transcription of Farxiga’s DAPA-HF trial at ESC - astrazeneca.com
{{id}} {{{paragraph}}}
Example: confidence
Farxiga’s DAPA-HF trial at ESC - astrazeneca.com
Farxiga sDAPA-HF trial at ESCC onference call for investors and analysts1stSeptember 2019 Inorder,amongotherthings,toutilisethe'sa feharbour'provisionsoftheUSPrivateSecuri tiesLitigationReformAct1995,weareprovidi ngthefollowingcautionarystatement:thisdo cumentcontainscertainforward-lookingstat ementswithrespecttotheoperations,perform anceandfinancialconditionoftheGroup,incl uding,amongotherthings,statementsaboutex pectedrevenues,margins, ,anyforward-lookingstatements,bytheirver ynature, 'anticipates','believes','expects','inte nds' ,certainofwhicharebeyondourcontrol,inclu de,amongotherthings:thelossorexpirationo f,orlimitationsto,patents,marketingexclu sivityortrademarks,ortheriskoffailuretoo btainandenforcepatentprotection;effectso fpatentlitigationinrespectofIPrights;the impactofanydelaysinthemanufacturing,dist ributionandsaleofanyofourproducts;theimp actofanyfailurebythirdpartiestosupplymat erialsorservices;theriskoffailureofoutso urcing;therisksassociatedwithmanufacturi ngbiologics;theriskthatR&Dwillnotyieldne wproductsthatachievecommercials
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: